Pendahuluan
Halaman ini memberikan analisis komprehensif tentang sejarah perdagangan orang dalam yang diketahui dari Noubar Afeyan. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Adalah ilegal bagi orang dalam untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik yang tidak dipublikasikan. Ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan kepada SEC melalui Formulir 4. Terlepas dari pembatasan ini, penelitian akademis menunjukkan bahwa orang dalam - secara umum - cenderung mengungguli pasar di perusahaan mereka sendiri.
Rata-rata Profitabilitas Perdagangan
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari semua pembelian pasar terbuka yang dilakukan oleh orang dalam dalam tiga tahun terakhir. Untuk menghitung ini, kami memeriksa setiap pembelian pasar terbuka yang tidak direncanakan yang dilakukan oleh orang dalam, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata dari perdagangan tersebut selama 3, 6, dan 12 bulan, dengan merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami merata-ratakan semua metrik kinerja untuk menghitung metrik kinerja untuk orang dalam. Daftar ini hanya mencakup orang dalam yang telah melakukan setidaknya tiga perdagangan dalam dua tahun terakhir.
Jika profitabilitas perdagangan orang dalam ini adalah "N/A", maka orang dalam tersebut belum melakukan pembelian di pasar terbuka dalam tiga tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang andal.
Frekuensi Pembaruan: Setiap Hari
Lihat daftar pedagang dalam perusahaan yang paling menguntungkan.
Perusahaan dengan Posisi Orang Dalam yang Dilaporkan
Pengajuan SEC menunjukkan bahwa Noubar Afeyan telah melaporkan kepemilikan atau perdagangan di perusahaan-perusahaan berikut:
Cara Membaca Grafik
Grafik berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka yang tidak direncanakan yang dilakukan oleh Noubar Afeyan. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham digambarkan sebagai perubahan persentase kumulatif dalam harga saham. Misalnya, jika perdagangan orang dalam dilakukan pada 1 Januari 2019, grafik akan menunjukkan perubahan persentase harian sekuritas hingga saat ini. Jika harga saham naik dari $10 menjadi $15 selama periode ini, perubahan persentase kumulatif dalam harga saham akan menjadi 50%. Perubahan harga dari $10 menjadi $20 akan menjadi 100%, dan perubahan harga dari $10 menjadi $5 akan menjadi -50%.
Pada akhirnya, kita mencoba menentukan seberapa erat korelasi perdagangan orang dalam dengan pengembalian berlebih (positif atau negatif) pada harga saham untuk melihat apakah orang dalam tersebut mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi orang dalam. Pertimbangkan situasi di mana orang dalam melakukan hal ini. Dalam situasi ini, kita akan mengharapkan (a) pengembalian positif setelah pembelian, atau (b) pengembalian negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, menunjukkan pengembalian positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, menunjukkan pengembalian negatif setelah setiap transaksi penjualan.
Namun, ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam tren kenaikan non-siklikal selama bertahun-tahun, maka kita akan mengharapkan semua plot pasca-pembelian memiliki kemiringan ke atas. Demikian pula, penurunan non-siklikal selama bertahun-tahun akan menghasilkan plot pasca-perdagangan dengan kemiringan ke bawah. Tak satu pun dari grafik ini akan menunjukkan aktivitas perdagangan orang dalam.
Indikator terkuat adalah situasi di mana harga saham sangat siklikal, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat menunjukkan adanya orang dalam yang mengatur waktu perdagangan untuk keuntungan finansial mereka.
Pembelian Orang Dalam AGIO / Agios Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam AGIO / Agios Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam BGMD / BG Medicine, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam BGMD / BG Medicine, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CARM / Carisma Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CARM / Carisma Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam EDIT / Editas Medicine, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam EDIT / Editas Medicine, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam EVLO / Evelo Biosciences, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam EVLO / Evelo Biosciences, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam FHTX / Foghorn Therapeutics Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam FHTX / Foghorn Therapeutics Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam KLDO / Kaleido Biosciences, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam KLDO / Kaleido Biosciences, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam MCRB / Seres Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam MCRB / Seres Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam QTRX / Quanterix Corporation - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam QTRX / Quanterix Corporation - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam RNAC / Cartesian Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam RNAC / Cartesian Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SANA / Sana Biotechnology, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SANA / Sana Biotechnology, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SYRS / Syros Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SYRS / Syros Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam TMDX / TransMedics Group, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam TMDX / TransMedics Group, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di AGIO / Agios Pharmaceuticals, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Sejarah Perdagangan Orang Dalam
Tabel ini menunjukkan daftar lengkap transaksi orang dalam yang dilakukan oleh Noubar Afeyan sebagaimana diungkapkan kepada Komisi Bursa Efek (Securities Exchange Commission/SEC).
Tanggal File | Tanggal Transaksi | Formulir | Ticker | Keamanan | Kode | Saham | Sisa Saham | Persen Ubah |
Bagikan Harga |
Tran Nilai |
Sisa Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,309 | 2,224,015 | -0.06 | 121.62 | -159,204 | 270,491,154 |
2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,428 | 2,225,324 | -0.15 | 120.88 | -414,377 | 268,997,610 |
2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,664 | 2,228,752 | -0.25 | 119.84 | -678,754 | 267,085,839 |
2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,599 | 2,234,416 | -0.21 | 118.96 | -547,107 | 265,811,043 |
2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,000 | 2,239,015 | -0.09 | 119.01 | -238,026 | 266,471,892 |
2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,832 | 2,241,015 | -0.30 | 118.30 | -808,208 | 265,106,248 |
2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,500 | 2,247,847 | -0.16 | 117.25 | -410,376 | 263,560,960 |
2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,668 | 2,251,347 | -0.12 | 116.33 | -310,362 | 261,893,568 |
2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2,254,015 | -0.03 | 124.61 | -87,230 | 280,882,501 |
2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,699 | 2,254,715 | -0.30 | 123.82 | -829,478 | 279,181,517 |
2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,900 | 2,261,414 | -0.13 | 122.86 | -356,298 | 277,840,490 |
2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,100 | 2,264,314 | -0.09 | 121.57 | -255,297 | 275,272,427 |
2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,601 | 2,266,414 | -0.11 | 120.86 | -314,347 | 273,910,637 |
2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -500 | 2,269,015 | -0.02 | 119.95 | -59,976 | 272,172,887 |
2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 2,269,515 | -0.05 | 119.28 | -131,211 | 270,714,331 |
2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,000 | 2,270,615 | -0.13 | 117.83 | -353,483 | 267,541,116 |
2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,279 | 2,273,615 | -0.19 | 117.18 | -501,418 | 266,424,934 |
2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,121 | 2,277,894 | -0.27 | 116.01 | -710,089 | 264,255,294 |
2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2,284,015 | 0.00 | 134.05 | -13,405 | 306,172,211 |
2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2,284,115 | -0.03 | 131.56 | -92,089 | 300,488,348 |
2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,705 | 2,284,815 | -0.12 | 130.76 | -353,695 | 298,753,270 |
2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,300 | 2,287,520 | -0.10 | 129.84 | -298,631 | 297,010,911 |
2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,435 | 2,289,820 | -0.06 | 128.78 | -184,798 | 294,880,501 |
2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 2,291,255 | -0.05 | 127.50 | -140,254 | 292,143,032 |
2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 2,292,355 | -0.05 | 125.71 | -138,277 | 288,163,695 |
2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,500 | 2,293,455 | -0.07 | 124.90 | -187,352 | 286,455,970 |
2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,600 | 2,294,955 | -0.07 | 123.74 | -197,978 | 283,969,240 |
2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,460 | 2,296,555 | -0.11 | 122.69 | -301,814 | 281,761,347 |
2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2,299,015 | 0.00 | 136.92 | -13,692 | 314,781,134 |
2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,299,115 | -0.01 | 135.02 | -27,003 | 310,415,012 |
2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,840 | 2,299,315 | -0.30 | 134.09 | -917,197 | 308,322,506 |
2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,160 | 2,306,155 | -0.27 | 133.26 | -820,887 | 307,320,291 |
2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,700 | 2,312,315 | -0.07 | 132.22 | -224,782 | 305,744,695 |
2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,314,015 | -0.01 | 150.24 | -30,048 | 347,657,614 |
2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,400 | 2,314,215 | -0.06 | 149.39 | -209,150 | 345,726,827 |
2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,601 | 2,315,615 | -0.07 | 148.61 | -237,929 | 344,130,492 |
2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,397 | 2,317,216 | -0.28 | 147.55 | -943,876 | 341,904,757 |
2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,031 | 2,323,613 | -0.13 | 146.55 | -444,188 | 340,521,535 |
2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,263 | 2,326,644 | -0.05 | 145.57 | -183,861 | 338,700,735 |
2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -408 | 2,327,907 | -0.02 | 144.46 | -58,940 | 336,293,868 |
2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2,328,315 | -0.03 | 142.97 | -100,079 | 332,878,264 |
2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -1,232 | 1,528,557 | -0.08 | 149.40 | -184,065 | 228,372,224 | |
2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -6,420 | 7,930,725 | -0.08 | 149.40 | -959,172 | 1,184,880,452 | |
2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -31,531 | 1,529,789 | -2.02 | 148.29 | -4,675,871 | 226,859,142 | |
2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -163,649 | 7,937,145 | -2.02 | 148.29 | -24,268,230 | 1,177,034,155 | |
2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,721 | 1,946,931 | -0.09 | 154.86 | -266,510 | 301,497,257 |
2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 1,948,652 | -0.02 | 153.71 | -61,484 | 299,527,299 |
2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,437 | 1,949,052 | -0.12 | 152.90 | -372,606 | 298,001,085 |
2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,902 | 1,951,489 | -0.20 | 151.76 | -592,172 | 296,160,312 |
2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,840 | 1,955,391 | -0.15 | 151.07 | -429,033 | 295,396,812 |
2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1,958,231 | -0.02 | 149.35 | -44,805 | 292,461,800 |
2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,800 | 1,958,531 | -0.09 | 148.57 | -267,428 | 290,980,909 |
2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 1,960,331 | -0.04 | 147.78 | -103,443 | 289,688,698 |
2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -900 | 1,961,031 | -0.05 | 145.91 | -131,323 | 286,142,662 |
2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,177 | 1,961,931 | -0.16 | 148.06 | -470,379 | 290,478,599 |
2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,229 | 1,965,108 | -0.11 | 146.82 | -327,261 | 288,516,567 |
2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,581 | 1,967,337 | -0.28 | 146.02 | -814,937 | 287,270,155 |
2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,400 | 1,972,918 | -0.12 | 144.99 | -347,966 | 286,045,095 |
2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,500 | 1,975,318 | -0.08 | 143.94 | -215,913 | 284,331,224 |
2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 1,976,818 | -0.06 | 142.82 | -157,102 | 282,329,147 |
2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,013 | 1,977,918 | -0.15 | 141.72 | -427,017 | 280,320,429 |
2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,000 | 1,980,931 | -0.05 | 141.01 | -141,010 | 279,331,080 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -97 | 1,981,931 | 0.00 | 164.67 | -15,973 | 326,364,578 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -625 | 1,982,028 | -0.03 | 163.92 | -102,451 | 324,896,408 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,223 | 1,982,653 | -0.11 | 163.02 | -362,401 | 323,219,230 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,005 | 1,984,876 | -0.05 | 162.19 | -163,003 | 321,930,611 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -825 | 1,985,881 | -0.04 | 160.24 | -132,194 | 318,208,635 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,200 | 1,986,706 | -0.11 | 159.57 | -351,050 | 317,015,299 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,923 | 1,988,906 | -0.10 | 158.25 | -304,320 | 314,750,142 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,802 | 1,990,829 | -0.09 | 157.41 | -283,656 | 313,379,777 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 1,992,631 | -0.03 | 155.66 | -93,396 | 310,172,941 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 1,993,231 | -0.01 | 153.84 | -30,768 | 306,638,657 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -800 | 1,993,431 | -0.04 | 152.92 | -122,336 | 304,835,469 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 1,994,231 | -0.04 | 151.73 | -106,213 | 302,590,453 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 1,994,931 | -0.02 | 150.60 | -60,238 | 300,426,634 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1,995,331 | -0.02 | 149.45 | -44,836 | 298,208,803 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 1,995,631 | -0.03 | 148.21 | -88,924 | 295,765,885 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1,996,231 | -0.02 | 147.06 | -44,119 | 293,572,318 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 1,996,531 | -0.01 | 145.03 | -14,503 | 289,556,891 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 1,996,631 | -0.01 | 144.40 | -28,879 | 288,303,533 |
2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 1,996,831 | -0.01 | 142.95 | -14,295 | 285,446,991 |
2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 1,996,931 | -0.01 | 129.15 | -25,830 | 257,903,639 |
2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,711 | 1,997,131 | -0.29 | 128.75 | -735,272 | 257,123,826 |
2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,600 | 2,002,842 | -0.13 | 127.71 | -332,036 | 255,775,541 |
2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,001 | 2,005,442 | -0.10 | 126.62 | -253,368 | 253,930,670 |
2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,488 | 2,007,443 | -0.22 | 125.53 | -563,357 | 251,984,483 |
2024-05-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7,996 | 2,011,931 | -0.40 | 122.07 | -976,063 | 245,594,204 |
2024-05-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,004 | 2,019,927 | -0.25 | 121.59 | -608,416 | 245,594,844 |
2024-05-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,000 | 2,024,931 | -0.10 | 120.37 | -240,741 | 243,741,957 |
2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2,026,931 | -0.03 | 113.40 | -79,379 | 229,851,138 |
2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,500 | 2,027,631 | -0.07 | 112.77 | -169,151 | 228,650,473 |
2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,246 | 2,029,131 | -0.21 | 111.55 | -473,650 | 226,353,621 |
2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,572 | 2,033,377 | -0.22 | 110.42 | -504,860 | 224,534,232 |
2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,982 | 2,037,949 | -0.20 | 109.70 | -436,815 | 223,557,707 |
2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 2,041,931 | -0.05 | 109.91 | -120,901 | 224,428,636 |
2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,153 | 2,043,031 | -0.20 | 109.04 | -452,847 | 222,774,143 |
2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,821 | 2,047,184 | -0.28 | 108.30 | -630,388 | 221,700,815 |
2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,926 | 2,053,005 | -0.19 | 107.16 | -420,700 | 219,994,473 |
2024-04-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -282 | 2,056,931 | -0.01 | 104.49 | -29,466 | 214,927,897 |
2024-04-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,475 | 2,057,213 | -0.31 | 103.69 | -671,398 | 213,314,062 |
2024-04-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8,243 | 2,063,688 | -0.40 | 103.10 | -849,839 | 212,762,725 |
2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -389 | 2,071,931 | -0.02 | 109.36 | -42,542 | 226,592,176 |
2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -748 | 2,072,320 | -0.04 | 108.56 | -81,205 | 224,977,483 |
2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7,512 | 2,073,068 | -0.36 | 107.31 | -806,136 | 222,467,354 |
2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,351 | 2,080,580 | -0.30 | 106.59 | -676,982 | 221,778,385 |
2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2,086,931 | 0.00 | 104.15 | -10,415 | 217,353,864 |
2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,702 | 2,087,031 | -0.13 | 103.64 | -280,044 | 216,306,363 |
2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,500 | 2,089,733 | -0.17 | 102.64 | -359,252 | 214,497,091 |
2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,832 | 2,093,233 | -0.18 | 101.33 | -388,289 | 212,103,113 |
2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,167 | 2,097,065 | -0.15 | 100.66 | -318,775 | 211,080,497 |
2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,499 | 2,100,232 | -0.07 | 99.40 | -149,000 | 208,762,221 |
2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,101,731 | -0.01 | 97.47 | -19,494 | 204,855,721 |
2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,973 | 2,101,931 | -0.14 | 110.75 | -329,256 | 232,785,916 |
2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,544 | 2,104,904 | -0.22 | 110.24 | -500,931 | 232,044,827 |
2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,100 | 2,109,448 | -0.15 | 109.09 | -338,176 | 230,117,362 |
2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,466 | 2,112,548 | -0.07 | 107.79 | -158,020 | 227,711,126 |
2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 2,114,014 | -0.05 | 106.71 | -117,376 | 225,577,344 |
2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,817 | 2,115,114 | -0.09 | 105.73 | -192,106 | 223,624,446 |
2024-03-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,778 | 2,116,931 | -0.27 | 103.18 | -596,147 | 218,414,991 |
2024-03-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7,109 | 2,122,709 | -0.33 | 102.15 | -726,159 | 216,827,083 |
2024-03-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,113 | 2,129,818 | -0.10 | 101.05 | -213,514 | 215,213,849 |
2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,131,931 | -0.01 | 112.44 | -22,487 | 239,703,662 |
2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,404 | 2,132,131 | -0.07 | 111.69 | -156,806 | 238,127,264 |
2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,803 | 2,133,535 | -0.18 | 110.80 | -421,373 | 236,395,891 |
2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -412 | 2,137,338 | -0.02 | 109.50 | -45,113 | 234,033,381 |
2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 2,137,750 | -0.03 | 108.52 | -65,109 | 231,977,941 |
2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,300 | 2,138,350 | -0.11 | 107.66 | -247,617 | 230,213,692 |
2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,281 | 2,140,650 | -0.29 | 106.60 | -669,527 | 228,183,871 |
2023-11-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8,100 | 2,146,931 | -0.38 | 76.17 | -616,966 | 163,528,729 |
2023-11-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,900 | 2,155,031 | -0.09 | 75.30 | -143,066 | 162,269,309 |
2023-10-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 2,156,931 | -0.02 | 78.42 | -31,366 | 169,135,744 |
2023-10-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,100 | 2,157,331 | -0.14 | 77.34 | -239,754 | 166,847,764 |
2023-10-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,500 | 2,160,431 | -0.30 | 76.73 | -498,734 | 165,766,198 |
2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2,166,931 | 0.00 | 105.58 | -10,558 | 228,784,575 |
2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -500 | 2,167,031 | -0.02 | 104.82 | -52,408 | 227,139,521 |
2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,700 | 2,167,531 | -0.26 | 103.76 | -591,421 | 224,898,681 |
2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8,700 | 2,173,231 | -0.40 | 102.88 | -895,054 | 223,581,571 |
2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,866 | 2,181,931 | -0.18 | 104.04 | -402,206 | 227,001,119 |
2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,604 | 2,185,797 | -0.26 | 103.22 | -578,445 | 225,618,185 |
2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,700 | 2,191,401 | -0.12 | 102.03 | -275,486 | 223,592,369 |
2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,800 | 2,194,101 | -0.08 | 100.94 | -181,690 | 221,470,141 |
2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,030 | 2,195,901 | -0.05 | 100.02 | -103,018 | 219,628,748 |
2023-09-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,196,931 | -0.01 | 100.16 | -20,033 | 220,055,594 |
2023-09-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,596 | 2,197,131 | -0.21 | 99.49 | -457,245 | 218,587,510 |
2023-09-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,204 | 2,201,727 | -0.24 | 98.46 | -512,367 | 216,774,114 |
2023-09-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,006 | 2,206,931 | -0.05 | 105.77 | -106,404 | 233,424,885 |
2023-09-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,380 | 2,207,937 | -0.42 | 105.06 | -985,422 | 231,956,146 |
2023-09-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,614 | 2,217,317 | -0.21 | 103.87 | -479,265 | 230,316,930 |
2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -70,813 | 0 | -100.00 | ||||
2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -2,431,281 | 7,293,841 | -25.00 | ||||
2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -1,181,745 | 0 | -100.00 | ||||
2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -345,069 | 1,035,208 | -25.00 | ||||
2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -4,926,378 | 8,057,470 | -37.94 | ||||
2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -2,825,989 | 8,615,337 | -24.70 | ||||
2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2,221,931 | 0.00 | 114.32 | -11,432 | 254,011,152 |
2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -250 | 2,222,031 | -0.01 | 113.22 | -28,305 | 251,578,350 |
2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -900 | 2,222,281 | -0.04 | 112.17 | -100,957 | 249,283,038 |
2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,895 | 2,223,181 | -0.17 | 111.23 | -433,243 | 247,285,757 |
2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,400 | 2,227,076 | -0.06 | 110.26 | -154,363 | 245,555,841 |
2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,174 | 2,228,476 | -0.19 | 108.77 | -453,992 | 242,383,981 |
2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,281 | 2,232,650 | -0.19 | 108.21 | -463,229 | 241,585,903 |
2023-09-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1,982,209 | -0.02 | 108.91 | -32,674 | 215,888,923 |
2023-09-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,689 | 1,982,509 | -0.29 | 108.07 | -614,811 | 214,250,144 |
2023-09-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,011 | 1,988,198 | -0.45 | 107.27 | -966,608 | 213,273,602 |
2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 1,997,209 | -0.01 | 117.21 | -11,721 | 234,092,867 |
2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,336 | 1,997,309 | -0.22 | 116.57 | -505,463 | 232,833,500 |
2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,717 | 2,001,645 | -0.24 | 115.43 | -544,460 | 231,040,074 |
2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,847 | 2,006,362 | -0.29 | 114.64 | -670,307 | 230,011,547 |
2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2,012,209 | -0.01 | 116.46 | -34,938 | 234,341,860 |
2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,878 | 2,012,509 | -0.49 | 115.84 | -1,144,313 | 233,138,300 |
2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,657 | 2,022,387 | -0.18 | 115.16 | -421,125 | 232,889,593 |
2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -854 | 2,026,044 | -0.04 | 113.83 | -97,215 | 230,633,503 |
2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -311 | 2,026,898 | -0.02 | 112.61 | -35,022 | 228,252,227 |
2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2,027,209 | -0.01 | 99.50 | -29,850 | 201,707,296 |
2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,000 | 2,027,509 | -0.20 | 98.82 | -395,289 | 200,362,900 |
2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,200 | 2,031,509 | -0.06 | 98.07 | -117,679 | 199,221,555 |
2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,900 | 2,032,709 | -0.14 | 96.44 | -279,672 | 196,031,813 |
2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,600 | 2,035,609 | -0.08 | 95.70 | -153,124 | 194,812,870 |
2023-08-15 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
U - Other | -113,960 | 0 | -100.00 | 14.92 | -1,700,283 | ||
2023-08-15 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
U - Other | -683,760 | 0 | -100.00 | 14.92 | -10,201,699 | ||
2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,037,209 | -0.01 | 113.68 | -22,735 | 231,579,733 |
2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -900 | 2,037,409 | -0.04 | 112.59 | -101,328 | 229,385,156 |
2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,175 | 2,038,309 | -0.20 | 111.46 | -465,349 | 227,191,552 |
2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,725 | 2,042,484 | -0.47 | 110.59 | -1,075,464 | 225,873,404 |
2023-07-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,101 | 2,052,209 | -0.05 | 121.29 | -133,544 | 248,920,023 |
2023-07-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -11,499 | 2,053,310 | -0.56 | 120.50 | -1,385,632 | 247,424,266 |
2023-07-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,400 | 2,064,809 | -0.12 | 119.61 | -287,053 | 246,962,306 |
2023-07-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,149 | 2,067,209 | -0.25 | 126.08 | -649,185 | 260,633,504 |
2023-07-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,004 | 2,072,358 | -0.43 | 125.26 | -1,127,819 | 259,578,589 |
2023-07-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -847 | 2,081,362 | -0.04 | 124.14 | -105,147 | 258,382,152 |
2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2,082,209 | -0.01 | 127.15 | -38,145 | 264,752,874 |
2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,845 | 2,082,509 | -0.33 | 126.27 | -864,316 | 262,957,787 |
2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,865 | 2,089,354 | -0.28 | 125.61 | -736,678 | 262,434,981 |
2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,990 | 2,095,219 | -0.09 | 124.59 | -247,942 | 261,051,926 |
2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 3,246,753 | 3,931,685 | 474.03 | 2.31 | 7,499,999 | 9,082,192 | |
2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,082,251 | 1,493,241 | 263.33 | 2.31 | 2,500,000 | 3,449,387 | |
2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,082,251 | 1,493,241 | 263.33 | 2.31 | 2,500,000 | 3,449,387 | |
2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -170 | 2,097,209 | -0.01 | 128.17 | -21,789 | 268,801,794 |
2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,549 | 2,097,379 | -0.07 | 127.55 | -197,577 | 267,523,628 |
2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,012 | 2,098,928 | -0.05 | 126.54 | -128,055 | 265,590,793 |
2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,639 | 2,099,940 | -0.13 | 125.14 | -330,258 | 262,796,991 |
2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,097 | 2,102,579 | -0.29 | 124.17 | -757,086 | 261,084,593 |
2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,533 | 2,108,676 | -0.17 | 123.46 | -436,169 | 260,327,861 |
2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,096 | 2,112,209 | -0.10 | 122.82 | -257,441 | 259,432,070 |
2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8,073 | 2,114,305 | -0.38 | 121.87 | -983,873 | 257,674,790 |
2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,131 | 2,122,378 | -0.15 | 120.77 | -378,123 | 256,314,073 |
2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,700 | 2,125,509 | -0.08 | 119.84 | -203,723 | 254,714,835 |
2023-06-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 2,127,209 | -0.02 | 123.48 | -49,390 | 262,657,131 |
2023-06-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,790 | 2,127,609 | -0.32 | 122.26 | -830,175 | 260,130,838 |
2023-06-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7,810 | 2,134,399 | -0.36 | 121.60 | -949,662 | 259,533,527 |
2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -530 | 2,142,209 | -0.02 | 128.15 | -67,918 | 274,516,371 |
2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,002 | 2,142,739 | -0.14 | 127.19 | -381,823 | 272,533,902 |
2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,997 | 2,145,741 | -0.28 | 126.17 | -756,658 | 270,734,150 |
2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,471 | 2,151,738 | -0.25 | 125.43 | -686,229 | 269,892,928 |
2023-06-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,702 | 2,157,209 | -0.13 | 126.59 | -342,054 | 273,087,343 |
2023-06-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -12,298 | 2,159,911 | -0.57 | 125.76 | -1,546,547 | 271,621,768 |
2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -22,760 | 1,380,277 | -1.62 | 6.24 | -142,016 | 8,612,514 | |
2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -177,240 | 10,743,293 | -1.62 | 6.24 | -1,105,924 | 67,034,925 | |
2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -22,297 | 1,403,037 | -1.56 | 6.31 | -140,607 | 8,847,692 | |
2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -181,461 | 10,920,533 | -1.63 | 6.31 | -1,144,311 | 68,865,973 | |
2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 2,172,209 | -0.03 | 129.68 | -77,807 | 281,688,370 |
2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,441 | 2,172,809 | -0.11 | 128.55 | -313,780 | 279,305,037 |
2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,637 | 2,175,250 | -0.26 | 127.84 | -720,629 | 278,082,002 |
2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,373 | 2,180,887 | -0.15 | 126.72 | -427,440 | 276,370,942 |
2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,949 | 2,184,260 | -0.13 | 125.69 | -370,666 | 274,544,226 |
2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -9,330 | 1,425,334 | -0.65 | 6.23 | -58,093 | 8,874,842 | |
2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -72,670 | 11,101,994 | -0.65 | 6.23 | -452,480 | 69,126,566 | |
2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -13,127 | 1,434,664 | -0.91 | 6.35 | -83,385 | 9,113,273 | |
2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -102,245 | 11,174,664 | -0.91 | 6.35 | -649,481 | 70,983,701 | |
2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -39,580 | 1,447,791 | -2.66 | 6.57 | -259,851 | 9,505,037 | |
2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -308,290 | 11,276,909 | -2.66 | 6.57 | -2,023,986 | 74,035,163 | |
2023-03-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,187,209 | -0.46 | 139.00 | -1,390,000 | 304,022,051 |
2023-02-27 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 1,329,324 | 1,329,324 | 5.78 | 7,683,493 | 7,683,493 | ||
2023-02-27 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 1,993,986 | 7,508,693 | 36.16 | 5.78 | 11,525,239 | 43,400,246 | |
2023-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,197,209 | -0.45 | 160.35 | -1,603,500 | 352,322,463 |
2023-02-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,207,209 | -0.45 | 173.17 | -1,731,700 | 382,222,383 |
2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -11,000 | 2,217,209 | -0.49 | 169.32 | -1,862,516 | 375,416,941 |
2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,100 | 2,228,209 | -0.09 | 168.27 | -353,364 | 374,937,609 |
2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2,230,309 | -0.01 | 166.59 | -49,977 | 371,547,176 |
2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,700 | 2,230,609 | -0.17 | 165.83 | -613,577 | 369,905,459 |
2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,900 | 2,234,309 | -0.13 | 164.60 | -477,327 | 367,757,430 |
2023-01-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,237,209 | -0.44 | 194.33 | -1,943,300 | 434,756,825 |
2023-01-20 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,247,209 | -0.44 | 200.20 | -2,002,000 | 449,891,242 |
2023-01-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,257,209 | -0.44 | 188.57 | -1,885,700 | 425,641,901 |
2023-01-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,267,209 | -0.44 | 182.15 | -1,821,500 | 412,972,119 |
2022-12-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,277,209 | -0.44 | 201.70 | -2,017,000 | 459,313,055 |
2022-12-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,287,209 | -0.44 | 195.00 | -1,950,000 | 446,005,755 |
2022-12-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,297,209 | -0.43 | 172.16 | -1,721,600 | 395,487,501 |
2022-12-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,307,209 | -0.43 | 173.52 | -1,735,200 | 400,346,906 |
2022-11-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,317,209 | -0.43 | 178.01 | -1,780,100 | 412,486,374 |
2022-11-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,327,209 | -0.43 | 184.25 | -1,842,500 | 428,788,258 |
2022-11-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,337,209 | -0.43 | 162.50 | -1,625,000 | 379,796,462 |
2022-11-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,347,209 | -0.42 | 154.20 | -1,542,000 | 361,939,628 |
2022-10-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,357,209 | -0.42 | 137.25 | -1,372,500 | 323,526,935 |
2022-10-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,367,209 | -0.42 | 132.50 | -1,325,000 | 313,655,192 |
2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 3,048,780 | 3,048,780 | 1.64 | 4,999,999 | 4,999,999 | ||
2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 919,111 | 6,299,611 | 17.08 | 1.64 | 1,507,342 | 10,331,362 | |
2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 914,634 | 5,380,500 | 20.48 | 1.64 | 1,500,000 | 8,824,020 | |
2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 2,757,333 | 14,101,638 | 24.31 | 1.64 | 4,522,026 | 23,126,686 | |
2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 2,743,902 | 11,344,305 | 31.90 | 1.64 | 4,499,999 | 18,604,660 | |
2022-10-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,377,209 | -0.42 | 135.36 | -1,353,600 | 321,779,010 |
2022-10-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,387,209 | -0.42 | 122.40 | -1,224,000 | 292,194,382 |
2022-09-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,397,209 | -0.42 | 123.58 | -1,235,800 | 296,247,088 |
2022-09-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,407,209 | -0.41 | 130.37 | -1,303,700 | 313,827,837 |
2022-09-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,417,209 | -0.41 | 134.00 | -1,340,000 | 323,906,006 |
2022-09-16 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
P - Purchase | 210,743 | 1,188,920 | 21.54 | ||||
2022-09-16 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
P - Purchase | 722,590 | 1,865,767 | 63.21 | ||||
2022-09-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,427,209 | -0.41 | 129.68 | -1,296,800 | 314,760,463 |
2022-09-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,437,209 | -0.41 | 136.95 | -1,369,500 | 333,775,773 |
2022-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,447,209 | -0.41 | 165.24 | -1,652,400 | 404,376,815 |
2022-08-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,457,209 | -0.41 | 174.09 | -1,740,900 | 427,775,515 |
2022-08-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,467,209 | -0.40 | 167.99 | -1,679,900 | 414,466,440 |
2022-07-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,477,209 | -0.40 | 161.00 | -1,610,000 | 398,830,649 |
2022-07-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,487,209 | -0.40 | 167.00 | -1,670,000 | 415,363,903 |
2022-07-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,497,209 | -0.40 | 168.88 | -1,688,800 | 421,728,656 |
2022-07-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,497,209 | -0.40 | 168.88 | -1,688,800 | 421,728,656 |
2022-07-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,507,209 | -0.40 | 154.85 | -1,548,500 | 388,241,314 |
2022-07-07 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 5,825,495 | 5,825,495 | 3.15 | 18,350,309 | 18,350,309 | ||
2022-07-07 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 2,912,748 | 5,875,711 | 98.31 | 3.15 | 9,175,156 | 18,508,490 | |
2022-07-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,517,209 | -0.40 | 140.47 | -1,404,700 | 353,592,348 |
2022-06-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,527,209 | -0.39 | 127.69 | -1,276,900 | 322,699,317 |
2022-06-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,537,209 | -0.39 | 147.47 | -1,474,700 | 374,162,211 |
2022-06-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,547,209 | -0.39 | 146.31 | -1,463,100 | 372,682,149 |
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 13,698,630 | 13,698,630 | 1.46 | 20,000,000 | 20,000,000 | ||
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 6,849,315 | 8,219,791 | 499.78 | 1.46 | 10,000,000 | 12,000,895 | |
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,369,863 | 5,495,324 | 33.21 | 1.46 | 2,000,000 | 8,023,173 | |
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,095,890 | 1,887,419 | 138.45 | 1.46 | 1,599,999 | 2,755,632 | |
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 4,383,561 | 7,590,873 | 136.67 | 1.46 | 6,399,999 | 11,082,675 | |
2022-05-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,557,209 | -0.39 | 130.80 | -1,308,000 | 334,482,937 |
2022-05-20 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,567,209 | -0.39 | 138.38 | -1,383,800 | 355,250,381 |
2022-05-13 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -100 | 5,816,657 | 0.00 | 136.00 | -13,600 | 791,065,352 | |
2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -49,900 | 5,816,757 | -0.85 | 135.36 | -6,754,714 | 787,385,311 | |
2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -24,567 | 5,866,657 | -0.42 | 134.04 | -3,293,015 | 786,379,611 | |
2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -25,433 | 5,891,224 | -0.43 | 133.11 | -3,385,282 | 784,156,673 | |
2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -31,618 | 5,916,657 | -0.53 | 132.22 | -4,180,674 | 782,327,013 | |
2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -51,256 | 5,948,275 | -0.85 | 131.45 | -6,737,478 | 781,886,473 | |
2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -41,182 | 5,999,531 | -0.68 | 130.08 | -5,356,765 | 780,391,395 | |
2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -75,944 | 6,040,713 | -1.24 | 129.39 | -9,826,257 | 781,596,982 | |
2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,229,673 | -0.45 | 130.74 | -1,307,400 | 291,507,448 |
2022-05-02 |
|
4 | MRNA |
Moderna, Inc.
Restricted Stock Units |
M - Exercise | -703 | 0 | -100.00 | ||||
2022-05-02 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 5,415 | 5,415 | |||||
2022-05-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | 703 | 2,239,673 | 0.03 | ||||
2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1,579,843 | 4,465,866 | 54.74 | 1.91 | 3,017,500 | 8,529,804 | |
2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 947,905 | 2,004,657 | 89.70 | 1.91 | 1,810,499 | 3,828,895 | |
2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 3,791,623 | 8,600,403 | 78.85 | 1.91 | 7,242,000 | 16,426,770 | |
2022-02-14 |
|
5 | MRNA |
Moderna, Inc.
Common Stock |
G - Gift | -100,000 | 2,238,970 | -4.28 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1,666,666 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -5,000,000 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1,666,667 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3,333,333 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -13,333,333 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -666,667 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -2,666,667 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3,000,000 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -27,388,000 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -22,275,232 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -4,112,000 | 0 | -100.00 | ||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 294,117 | 1,617,646 | 22.22 | 17.00 | 4,999,989 | 27,499,982 | |
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 1,323,529 | 1,323,529 | |||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 661,764 | 5,514,707 | 13.64 | 17.00 | 11,249,988 | 93,750,019 | |
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 4,852,943 | 4,852,943 | |||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 970,588 | 970,588 | |||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 220,588 | 8,617,413 | 2.63 | 17.00 | 3,749,996 | 146,496,021 | |
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 8,396,825 | 8,396,825 | |||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 5,896,386 | 5,896,386 | |||||
2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 1,088,470 | 1,088,470 | |||||
2021-07-30 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 19,852 | 19,852 | |||||
2021-07-29 | 3 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
2,197,059 | ||||||||
2021-05-19 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -295,171 | 2,962,963 | -9.06 | ||||
2021-05-13 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Restricted Stock Units |
A - Award | 703 | 703 | |||||
2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 4,081 | 4,081 | |||||
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,888 | 9,116,657 | -0.05 | 121.07 | -591,810 | 1,103,790,130 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,000 | 9,121,545 | -0.01 | 123.44 | -123,440 | 1,125,963,515 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -31,943 | 9,122,545 | -0.35 | 123.08 | -3,931,538 | 1,122,801,014 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -14,379 | 9,154,488 | -0.16 | 121.71 | -1,750,038 | 1,114,173,510 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -225,732 | 9,168,867 | -2.40 | 120.76 | -27,259,283 | 1,107,227,794 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -344,542 | 9,394,599 | -3.54 | 119.81 | -41,278,061 | 1,125,525,570 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -611,922 | 9,739,141 | -5.91 | 118.90 | -72,758,505 | 1,157,999,448 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -883,277 | 10,351,063 | -7.86 | 118.04 | -104,265,815 | 1,221,883,986 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -558 | 11,234,340 | 0.00 | 131.30 | -73,265 | 1,475,068,842 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,610 | 11,234,898 | -0.06 | 130.56 | -862,994 | 1,466,814,801 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -83,242 | 11,241,508 | -0.74 | 129.54 | -10,783,377 | 1,456,253,050 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -123,374 | 11,324,750 | -1.08 | 128.74 | -15,883,527 | 1,457,981,157 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -46,872 | 11,448,124 | -0.41 | 127.47 | -5,974,788 | 1,459,295,801 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -82,557 | 11,494,996 | -0.71 | 126.40 | -10,434,924 | 1,452,928,411 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -116,383 | 11,577,553 | -1.00 | 125.36 | -14,589,226 | 1,451,307,630 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -251,545 | 11,693,936 | -2.11 | 124.42 | -31,296,927 | 1,454,945,484 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -639,681 | 11,945,481 | -5.08 | 123.50 | -78,998,365 | 1,475,225,094 |
2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -284,300 | 12,585,162 | -2.21 | 122.53 | -34,836,672 | 1,542,121,567 |
2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70,000 | 2,633,703 | 2.73 | 29.00 | 2,030,000 | 76,377,387 | |
2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70,000 | 2,633,703 | 2.73 | 29.00 | 2,030,000 | 76,377,387 | |
2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70,000 | 15,393,593 | 0.46 | 29.00 | 2,030,000 | 446,414,197 | |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -23,423 | 14,623,159 | -0.16 | 151.29 | -3,543,551 | 2,212,266,072 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -190,710 | 14,646,582 | -1.29 | 150.51 | -28,704,468 | 2,204,511,249 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -179,268 | 14,837,292 | -1.19 | 149.63 | -26,823,154 | 2,220,044,653 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -268,688 | 15,016,560 | -1.76 | 148.52 | -39,905,810 | 2,230,274,508 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -292,483 | 15,285,248 | -1.88 | 147.57 | -43,162,565 | 2,255,688,375 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -307,795 | 15,577,731 | -1.94 | 146.64 | -45,134,105 | 2,284,270,183 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -357,316 | 15,885,526 | -2.20 | 145.48 | -51,982,439 | 2,311,031,088 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -405,551 | 16,242,842 | -2.44 | 144.55 | -58,623,573 | 2,347,949,915 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -397,126 | 16,648,393 | -2.33 | 143.57 | -57,017,127 | 2,390,283,036 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -117,011 | 17,045,519 | -0.68 | 142.76 | -16,704,549 | 2,433,426,815 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -70,631 | 17,162,530 | -0.41 | 141.46 | -9,991,271 | 2,427,765,155 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -102,852 | 17,233,161 | -0.59 | 140.24 | -14,423,553 | 2,416,709,566 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -56,435 | 17,336,013 | -0.32 | 139.64 | -7,880,849 | 2,420,882,335 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -46,222 | 17,392,448 | -0.27 | 138.56 | -6,404,451 | 2,409,871,506 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -122,142 | 17,438,670 | -0.70 | 137.29 | -16,768,948 | 2,394,165,468 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,985 | 17,560,812 | -0.06 | 136.48 | -1,362,773 | 2,396,734,743 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -30,968 | 17,570,797 | -0.18 | 170.03 | -5,265,421 | 2,987,523,958 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -54,274 | 17,601,735 | -0.31 | 169.14 | -9,179,910 | 2,977,159,218 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -58,377 | 17,656,009 | -0.33 | 168.11 | -9,813,857 | 2,968,181,688 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -122,715 | 17,714,386 | -0.69 | 167.10 | -20,505,750 | 2,960,084,529 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -351,578 | 17,837,101 | -1.93 | 166.30 | -58,466,296 | 2,966,252,818 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -165,578 | 18,188,311 | -0.90 | 165.47 | -27,397,976 | 3,009,596,176 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -189,200 | 18,353,889 | -1.02 | 164.13 | -31,054,266 | 3,012,508,229 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -366,471 | 18,543,089 | -1.94 | 163.25 | -59,827,380 | 3,027,209,346 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -250,501 | 18,909,560 | -1.31 | 162.36 | -40,672,044 | 3,070,209,108 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -30,808 | 19,160,061 | -0.16 | 160.96 | -4,958,809 | 3,083,974,678 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -54,409 | 19,190,869 | -0.28 | 160.37 | -8,725,620 | 3,077,656,933 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -161,887 | 19,245,278 | -0.83 | 159.18 | -25,769,076 | 3,063,451,805 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -35,000 | 12,869,462 | -0.27 | 150.41 | -5,264,350 | 1,935,695,779 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -99,005 | 12,904,462 | -0.76 | 148.91 | -14,742,765 | 1,921,594,403 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -267,038 | 13,003,467 | -2.01 | 148.01 | -39,523,921 | 1,924,624,946 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -288,656 | 13,270,505 | -2.13 | 147.17 | -42,481,157 | 1,953,004,296 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -351,112 | 13,559,161 | -2.52 | 146.05 | -51,281,277 | 1,980,368,345 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -354,358 | 13,910,273 | -2.48 | 145.04 | -51,396,616 | 2,017,566,861 |
2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -358,528 | 14,264,631 | -2.45 | 144.17 | -51,688,838 | 2,056,526,145 |
2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71,667 | 738,333 | 10.75 | 11.50 | 824,170 | 8,490,830 | |
2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71,667 | 738,333 | 10.75 | 11.50 | 824,170 | 8,490,830 | |
2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71,666 | 1,685,444 | 4.44 | 11.50 | 824,159 | 19,382,606 | |
2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -11,585,199 | 0 | -100.00 | ||||
2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -11,441,326 | 0 | -100.00 | ||||
2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -9,725,122 | 0 | -100.00 | ||||
2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -1,487,371 | 0 | -100.00 | ||||
2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 11,585,199 | 11,585,199 | |||||
2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 11,441,326 | 11,441,326 | |||||
2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 9,725,122 | 9,725,122 | |||||
2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 1,487,371 | 1,487,371 | |||||
2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 46,429 | 4,125,461 | 1.14 | 15.00 | 696,435 | 61,881,915 | |
2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 37,143 | 1,370,476 | 2.79 | 15.00 | 557,145 | 20,557,140 | |
2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 37,143 | 1,370,476 | 2.79 | 15.00 | 557,145 | 20,557,140 | |
2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 9,285 | 791,529 | 1.19 | 15.00 | 139,275 | 11,872,935 | |
2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,481,481 | 0 | -100.00 | ||||
2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -370,370 | 0 | -100.00 | ||||
2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -4,074,074 | 0 | -100.00 | ||||
2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -4,444,444 | 0 | -100.00 | ||||
2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
C - Conversion | 1,481,481 | 1,481,481 | |||||
2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
C - Conversion | 8,888,888 | 8,888,888 | |||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -43,154 | 0 | -100.00 | ||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -1,481,481 | 2,962,963 | -33.33 | ||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -1,186,310 | 3,258,134 | -26.69 | ||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -966,234 | 0 | -100.00 | ||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -642,180 | 1,283,282 | -33.35 | ||||
2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -3,587,820 | 4,434,600 | -44.72 | ||||
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3,333,333 | 0 | -100.00 | ||||
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -2,666,666 | 0 | -100.00 | ||||
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,336,293 | 0 | -100.00 | ||||
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -8,333,333 | 0 | -100.00 | ||||
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -7,500,000 | 0 | -100.00 | ||||
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
P - Purchase | 50,000 | 1,851,801 | 2.78 | 16.00 | 800,000 | 29,628,816 | |
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
P - Purchase | 50,000 | 1,851,801 | 2.78 | 16.00 | 800,000 | 29,628,816 | |
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 1,801,801 | 1,801,801 | |||||
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
P - Purchase | 50,000 | 1,491,441 | 3.47 | 16.00 | 800,000 | 23,863,056 | |
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 1,441,441 | 1,441,441 | |||||
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 722,320 | 9,280,878 | 8.44 | ||||
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 4,504,504 | 8,558,558 | 111.11 | ||||
2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 4,054,054 | 4,054,054 | |||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series C Preferred Stock |
C - Conversion | -660,048 | 0 | -100.00 | ||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series C Preferred Stock |
C - Conversion | -660,048 | 0 | -100.00 | ||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series B Preferred Stock |
C - Conversion | -2,416,666 | 0 | -100.00 | ||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series B Preferred Stock |
C - Conversion | -2,416,666 | 0 | -100.00 | ||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series A Preferred Stock |
C - Conversion | -4,250,000 | 0 | -100.00 | ||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series A Preferred Stock |
C - Conversion | -4,250,000 | 0 | -100.00 | ||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
P - Purchase | 165,000 | 1,143,177 | 16.87 | 15.00 | 2,475,000 | 17,147,655 | |
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 95,861 | 978,177 | 10.86 | ||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 95,861 | 978,177 | 10.86 | ||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 338,630 | 882,316 | 62.28 | ||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 338,630 | 882,316 | 62.28 | ||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 543,686 | 543,686 | |||||
2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 543,686 | 543,686 | |||||
2020-10-13 | 3 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
485,949 | ||||||||
2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -2,053,049 | 0 | -100.00 | ||||
2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1,449,190 | 4,971,576 | -22.57 | ||||
2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -7,550,810 | 14,435,589 | -34.34 | ||||
2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,666,667 | 4,079,032 | 69.09 | 3.75 | 6,250,001 | 15,296,370 | |
2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,333,333 | 1,333,333 | 3.75 | 4,999,999 | 4,999,999 | ||
2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,333,333 | 1,333,333 | 3.75 | 4,999,999 | 4,999,999 | ||
2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 333,333 | 782,244 | 74.25 | 3.75 | 1,249,999 | 2,933,415 | |
2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666,666 | 666,666 | 7.50 | 4,999,995 | 4,999,995 | ||
2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666,667 | 2,910,972 | 29.70 | 7.50 | 5,000,002 | 21,832,290 | |
2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666,667 | 2,910,972 | 29.70 | 7.50 | 5,000,002 | 21,832,290 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -10,746 | 6,420,766 | -0.17 | 70.18 | -754,113 | 450,584,959 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -69,254 | 6,431,512 | -1.07 | 69.45 | -4,809,448 | 446,645,998 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -56,406 | 21,986,399 | -0.26 | 70.18 | -3,958,353 | 1,542,919,735 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -363,594 | 22,042,805 | -1.62 | 69.45 | -25,250,331 | 1,530,795,657 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -367 | 6,500,766 | -0.01 | 72.44 | -26,584 | 470,886,236 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -2,551 | 6,501,133 | -0.04 | 71.51 | -182,433 | 464,924,626 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -3,900 | 6,503,684 | -0.06 | 70.46 | -274,780 | 458,226,161 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -7,443 | 6,507,584 | -0.11 | 68.81 | -512,185 | 447,814,838 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -23,199 | 6,515,027 | -0.35 | 67.15 | -1,557,822 | 437,486,669 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -42,540 | 6,538,226 | -0.65 | 65.77 | -2,797,690 | 429,993,625 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -1,933 | 22,406,399 | -0.01 | 72.44 | -140,017 | 1,623,009,752 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -13,408 | 22,408,332 | -0.06 | 71.51 | -958,861 | 1,602,511,695 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -20,492 | 22,421,740 | -0.09 | 70.46 | -1,443,793 | 1,579,755,082 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -39,082 | 22,442,232 | -0.17 | 68.81 | -2,689,404 | 1,544,348,730 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -121,771 | 22,481,314 | -0.54 | 67.15 | -8,176,971 | 1,509,629,228 | |
2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -223,314 | 22,603,085 | -0.98 | 65.77 | -14,686,491 | 1,486,516,748 | |
2020-05-26 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1,900,000 | 2,886,023 | 192.69 | 4.75 | 9,025,000 | 13,708,609 | |
2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 380,000 | 1,056,752 | 56.15 | 4.75 | 1,805,000 | 5,019,572 | |
2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1,520,000 | 4,808,780 | 46.22 | 4.75 | 7,220,000 | 22,841,705 | |
2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -2,281,179 | 0 | -100.00 | ||||
2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1,610,000 | 6,580,766 | -19.66 | ||||
2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -8,390,000 | 22,826,399 | -26.88 | ||||
2020-04-30 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 18,270 | 18,270 | |||||
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -38,366 | 8,190,766 | -0.47 | 18.65 | -715,710 | 152,797,102 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -199,935 | 31,216,399 | -0.64 | 18.65 | -3,729,747 | 582,335,680 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -4,092 | 8,229,132 | -0.05 | 18.96 | -77,579 | 156,012,822 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -21,325 | 31,416,334 | -0.07 | 18.96 | -404,292 | 595,609,710 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -27,714 | 8,233,224 | -0.34 | 18.99 | -526,408 | 156,384,327 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -144,423 | 31,437,659 | -0.46 | 18.99 | -2,743,199 | 597,133,183 | |
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1,735,720 | 0 | -100.00 | ||||
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1,207,658 | 8,260,938 | -12.75 | ||||
2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -6,292,342 | 31,582,082 | -16.61 | ||||
2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -248,379 | 0 | -100.00 | ||||
2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -61,537 | 0 | -100.00 | ||||
2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -1,061,102 | 0 | -100.00 | ||||
2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -1,469,173 | 0 | -100.00 | ||||
2019-06-28 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 54,660 | 54,660 | |||||
2019-06-20 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 4,444,444 | 4,444,444 | 2.25 | 9,999,999 | 9,999,999 | ||
2019-06-20 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 4,444,444 | 4,444,444 | 2.25 | 9,999,999 | 9,999,999 | ||
2019-06-14 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
2019-06-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Stock Option (Right to Buy) |
A - Award | 15,690 | 15,690 | |||||
2019-05-28 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -895,255 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -89,525 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -358,102 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -151,643 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -617,914 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -222,506 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -1,005,413 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -928,074 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -386,697 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series A Preferred Stock |
C - Conversion | -4,153,847 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series A Preferred Stock |
C - Conversion | -1,384,615 | 0 | -100.00 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 500,000 | 986,023 | 102.88 | 20.00 | 10,000,000 | 19,720,460 | |
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 486,023 | 486,023 | |||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 48,602 | 676,752 | 7.74 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 194,409 | 3,288,780 | 6.28 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 82,324 | 628,150 | 15.08 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 335,457 | 3,094,371 | 12.16 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 120,795 | 1,761,029 | 7.36 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 545,826 | 545,826 | |||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 503,840 | 2,758,914 | 22.34 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 209,933 | 1,640,234 | 14.68 | ||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 2,255,074 | 2,255,074 | |||||
2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 751,691 | 1,430,301 | 110.77 | ||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -1,682,665 | 0 | -100.00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series F Convertible Preferred Stock |
C - Conversion | -450,958 | 0 | -100.00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -600,000 | 0 | -100.00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1,257,465 | 0 | -100.00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series F Convertible Preferred Stock |
C - Conversion | -992,110 | 0 | -100.00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -1,400,000 | 0 | -100.00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -2,000,000 | 0 | -100.00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
C - Conversion | 792,366 | 1,061,102 | 294.85 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
C - Conversion | 1,254,888 | 1,469,173 | 585.62 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | 268,736 | 268,736 | |||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -940,579 | 0 | -100.00 | ||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | 214,285 | 214,285 | |||||
2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -750,000 | 0 | -100.00 | ||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -1,251,251 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -1,251,251 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -2,570,694 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -1,928,021 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -642,674 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -1,278,720 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -852,480 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -9,275,111 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -3,091,704 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 333,333 | 2,244,305 | 17.44 | 15.00 | 4,999,995 | 33,664,575 | |
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 333,333 | 2,244,305 | 17.44 | 15.00 | 4,999,995 | 33,664,575 | |
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 266,667 | 2,560,096 | 11.63 | 15.00 | 4,000,005 | 38,401,440 | |
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 625,625 | 1,910,972 | 48.67 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 625,625 | 1,910,972 | 48.67 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 1,285,347 | 1,285,347 | |||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 964,010 | 5,601,565 | 20.79 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 321,337 | 2,293,429 | 16.29 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 639,360 | 639,360 | |||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 426,240 | 1,972,092 | 27.57 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 4,637,555 | 4,637,555 | |||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 1,545,852 | 1,545,852 | |||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -562,407 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -347,173 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -1,331,816 | 0 | -100.00 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 281,203 | 947,111 | 42.23 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 173,586 | 216,451 | 404.96 | ||||
2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 665,908 | 665,908 | |||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series D Preferred Stock |
C - Conversion | -21,496 | 0 | -100.00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series D Preferred Stock |
C - Conversion | -85,989 | 0 | -100.00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series C Preferred Stock |
C - Conversion | -1,428,432 | 0 | -100.00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series C Preferred Stock |
C - Conversion | -5,713,739 | 0 | -100.00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series B Preferred Stock |
C - Conversion | -6,195,632 | 0 | -100.00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series B Preferred Stock |
C - Conversion | -24,782,551 | 0 | -100.00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series A Preferred Stock |
C - Conversion | -1,823,036 | 0 | -100.00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series A Preferred Stock |
C - Conversion | -7,292,145 | 0 | -100.00 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 21,496 | 9,468,596 | 0.23 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 85,989 | 37,874,424 | 0.23 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 1,428,432 | 9,447,100 | 17.81 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 5,713,739 | 37,788,435 | 17.81 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 6,195,632 | 8,018,668 | 339.85 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 24,782,551 | 32,074,696 | 339.85 | ||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 1,823,036 | 1,823,036 | |||||
2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 7,292,145 | 7,292,145 | |||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -781,860 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -195,466 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -195,466 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1,781,843 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -593,948 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -593,948 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -5,000,000 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -5,000,000 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3,830,402 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -15,323,593 | 0 | -100.00 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 781,860 | 2,563,703 | 43.88 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 195,466 | 5,789,414 | 3.49 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 195,466 | 5,789,414 | 3.49 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 1,781,843 | 1,781,843 | |||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 593,948 | 5,593,948 | 11.88 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 593,948 | 5,593,948 | 11.88 | ||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 5,000,000 | 5,000,000 | |||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 5,000,000 | 5,000,000 | |||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 3,830,402 | 3,830,402 | |||||
2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 15,323,593 | 15,323,593 | |||||
2018-07-18 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
2018-06-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -4,643,963 | 0 | -100.00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -18,611,110 | 0 | -100.00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-3 Preferred Stock |
C - Conversion | -8,333,000 | 0 | -100.00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-2 Preferred Stock |
C - Conversion | -5,416,667 | 0 | -100.00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -10,102,055 | 0 | -100.00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -12,536,945 | 0 | -100.00 | ||||
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 281,250 | 18,233,403 | 1.57 | 16.00 | 4,500,000 | 291,734,448 | |
2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
C - Conversion | 14,622,143 | 17,952,153 | 439.10 | ||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
2018-02-13 |
|
5 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
G - Gift | -24,527 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series C Preferred Stock |
C - Conversion | -352,800 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series B Preferred Stock |
C - Conversion | -1,533,214 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series A-2 Preferred Stock |
C - Conversion | -3,360,000 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series A-1 Preferred Stock |
C - Conversion | -1,280,000 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 109,770 | 2,030,495 | 5.72 | ||||
2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 477,042 | 1,920,725 | 33.04 | ||||
2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 1,045,426 | 1,443,683 | 262.50 | ||||
2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 398,257 | 398,257 | |||||
2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series B-1 Preferred Stock |
C - Conversion | -156,250 | 0 | -100.00 | ||||
2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-2 Preferred Stock |
C - Conversion | -125,000 | 0 | -100.00 | ||||
2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-1 Preferred Stock |
C - Conversion | -8,324,999 | 0 | -100.00 | ||||
2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 8,606,249 | 8,918,749 | 2,754.00 | ||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625,000 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625,000 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625,000 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625,000 | ||||||||
2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -54,293 | 0 | -100.00 | ||||
2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -306,222 | 612,442 | -33.33 | ||||
2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -1,295,997 | 2,378,663 | -35.27 | ||||
2017-06-21 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -10,293 | 106,787 | -8.79 | 3.10 | -31,908 | 331,040 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -41,178 | 426,885 | -8.80 | 3.10 | -127,652 | 1,323,344 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -3,118 | 117,080 | -2.59 | 3.16 | -9,853 | 369,973 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -12,482 | 468,063 | -2.60 | 3.16 | -39,443 | 1,479,079 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -47,090 | 120,198 | -28.15 | 3.17 | -149,275 | 381,028 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -188,367 | 480,545 | -28.16 | 3.17 | -597,123 | 1,523,328 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -28,163 | 167,288 | -14.41 | 3.18 | -89,558 | 531,976 | |
2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -112,731 | 668,912 | -14.42 | 3.18 | -358,485 | 2,127,140 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -64,509 | 195,451 | -24.81 | 3.75 | -241,909 | 732,941 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -258,214 | 781,643 | -24.83 | 3.75 | -968,302 | 2,931,161 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -10,778 | 259,960 | -3.98 | 3.39 | -36,537 | 881,264 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -43,139 | 1,039,857 | -3.98 | 3.39 | -146,241 | 3,525,115 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -1,939 | 270,738 | -0.71 | 3.31 | -6,418 | 896,143 | |
2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -7,761 | 1,082,996 | -0.71 | 3.31 | -25,689 | 3,584,717 | |
2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -536 | 272,677 | -0.20 | 4.16 | -2,230 | 1,134,336 | |
2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -2,145 | 1,090,757 | -0.20 | 4.16 | -8,923 | 4,537,549 | |
2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -8,802 | 273,213 | -3.12 | 4.18 | -36,792 | 1,142,030 | |
2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -35,209 | 1,092,902 | -3.12 | 4.18 | -147,174 | 4,568,330 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -8,145 | 282,015 | -2.81 | 4.51 | -36,734 | 1,271,888 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -32,597 | 1,128,111 | -2.81 | 4.51 | -147,012 | 5,087,781 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -52,985 | 1,833,802 | -2.81 | 4.51 | -238,962 | 8,270,447 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -3,108 | 290,160 | -1.06 | 4.63 | -14,390 | 1,343,441 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -12,441 | 1,160,708 | -1.06 | 4.63 | -57,602 | 5,374,078 | |
2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -20,221 | 1,886,787 | -1.06 | 4.63 | -93,623 | 8,735,824 | |
2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -50,271 | 0 | -100.00 | ||||
2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -300,000 | 691,060 | -30.27 | ||||
2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -1,200,000 | 2,764,256 | -30.27 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -444,995 | 0 | -100.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1,779,981 | 0 | -100.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-3 Preferred Stock |
C - Conversion | -1,500,000 | 0 | -100.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-3 Preferred Stock |
C - Conversion | -6,000,000 | 0 | -100.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1,000,000 | 0 | -100.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock |
C - Conversion | -4,000,000 | 0 | -100.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-1 Preferred Stock |
C - Conversion | -200,000 | 0 | -100.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-1 Preferred Stock |
C - Conversion | -800,000 | 0 | -100.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 80,000 | 918,664 | 9.54 | 12.50 | 1,000,000 | 11,483,300 | |
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 320,000 | 3,674,660 | 9.54 | 12.50 | 4,000,000 | 45,933,250 | |
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 118,665 | 838,664 | 16.48 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 474,661 | 3,354,660 | 16.48 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 400,000 | 719,999 | 125.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,600,000 | 2,879,999 | 125.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 266,666 | 319,999 | 500.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,066,666 | 1,279,999 | 500.00 | ||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 53,333 | 53,333 | |||||
2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 213,333 | 213,333 | |||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -125,008 | 0 | -100.00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -241,718 | 0 | -100.00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -235,042 | 0 | -100.00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series B Convertible Preferred Stock |
C - Conversion | -631,458 | 0 | -100.00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series A Convertible Preferred Stock |
C - Conversion | -318,752 | 0 | -100.00 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 193,777 | 1,651,862 | 13.29 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 241,718 | 1,458,085 | 19.87 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 235,042 | 1,216,367 | 23.95 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 631,458 | 981,325 | 180.49 | ||||
2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 318,752 | 349,867 | 1,024.43 | ||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62,230 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62,230 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62,230 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62,230 | ||||||||
2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62,230 | ||||||||
2016-06-17 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -33,514 | 0 | -100.00 | ||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | 7 | 33,514 | 0.02 | ||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | 33,507 | 33,514 | 478,671.43 | ||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -200,000 | 1,925,462 | -9.41 | ||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -800,000 | 8,022,420 | -9.07 | ||||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -599,297 | 0 | -100.00 | 27.60 | -16,540,597 | ||
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -80,141 | 1,925,462 | -4.00 | 27.60 | -2,211,892 | 53,142,751 | |
2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -320,562 | 2,734,994 | -10.49 | 27.60 | -8,847,511 | 75,485,834 | |
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -199,999 | 0 | -100.00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1,051,060 | 0 | -100.00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-1 Preferred Stock |
C - Conversion | -1,325,708 | 0 | -100.00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -800,001 | 0 | -100.00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-2 Preferred Stock |
C - Conversion | -4,204,240 | 0 | -100.00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-1 Preferred Stock |
C - Conversion | -5,302,834 | 0 | -100.00 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 76,922 | 991,060 | 8.41 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 404,253 | 914,138 | 79.28 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 509,885 | 509,885 | |||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 307,692 | 3,964,256 | 8.41 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 1,617,015 | 3,656,564 | 79.28 | ||||
2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 2,039,549 | 2,039,549 | |||||
2015-12-11 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -2,508 | 0 | -100.00 | 0.56 | -1,404 | ||
2015-12-11 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -43,930 | 0 | -100.00 | 0.56 | -24,601 | ||
2015-11-20 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 5,000 | 5,000 | |||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -508 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -3,256 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -32 | 58,232 | -0.05 | 2.27 | -73 | 132,187 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 508 | 58,264 | 0.88 | 0.14 | 71 | 8,157 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57,756 | -0.03 | 2.27 | -36 | 131,106 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57,756 | -0.03 | 2.27 | -36 | 131,106 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57,756 | -0.03 | 2.27 | -36 | 131,106 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57,756 | -0.03 | 2.27 | -36 | 131,106 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57,772 | 0.44 | 0.14 | 36 | 8,088 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57,772 | 0.44 | 0.14 | 36 | 8,088 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57,772 | 0.44 | 0.14 | 36 | 8,088 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57,772 | 0.44 | 0.14 | 36 | 8,088 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -206 | 56,804 | -0.36 | 2.27 | -468 | 128,945 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 3,256 | 57,010 | 6.06 | 0.14 | 456 | 7,981 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -8,410 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4,205 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4,205 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4,205 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4,205 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -53,857 | 0 | -100.00 | ||||
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -530 | 786,970 | -0.07 | 2.27 | -1,203 | 1,786,422 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 8,410 | 787,500 | 1.08 | 0.14 | 1,177 | 110,250 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779,090 | -0.03 | 2.27 | -602 | 1,768,534 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779,090 | -0.03 | 2.27 | -602 | 1,768,534 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779,090 | -0.03 | 2.27 | -602 | 1,768,534 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779,090 | -0.03 | 2.27 | -602 | 1,768,534 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4,205 | 779,355 | 0.54 | 0.14 | 589 | 109,110 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4,205 | 779,355 | 0.54 | 0.14 | 589 | 109,110 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4,205 | 779,355 | 0.54 | 0.14 | 589 | 109,110 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4,205 | 779,355 | 0.54 | 0.14 | 589 | 109,110 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -3,390 | 763,330 | -0.44 | 2.27 | -7,695 | 1,732,759 | |
2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 53,857 | 766,720 | 7.56 | 0.14 | 7,540 | 107,341 | |
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
P - Purchase | 397,072 | 497,729 | 394.48 | 1.70 | 675,142 | 846,289 | |
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
C - Conversion | 100,657 | 100,657 | |||||
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
C - Conversion | |||||||
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
C - Conversion | |||||||
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
J - Other | |||||||
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
J - Other | |||||||
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
P - Purchase | 53,465 | 67,018 | 394.49 | 1.70 | 90,907 | 113,951 | |
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
C - Conversion | 13,553 | 13,553 | |||||
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
C - Conversion | |||||||
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
J - Other | |||||||
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
P - Purchase | 725,725 | 909,696 | 394.48 | 1.70 | 1,233,950 | 1,546,756 | |
2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
C - Conversion | 183,971 | 183,971 | |||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -454,546 | 0 | -100.00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,818,181 | 0 | -100.00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -224,719 | 0 | -100.00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -898,877 | 0 | -100.00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -599,297 | 0 | -100.00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1,526,338 | 0 | -100.00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -6,105,362 | 0 | -100.00 | ||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 599,297 | 599,297 | |||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 2,205,603 | 2,205,603 | |||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 8,822,420 | 8,822,420 | |||||
2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | 10,029 | 10,029 | |||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | 164,528 | 175,718 | 1,470.31 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -2,484,192 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -17,080 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -17,080 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -17,080 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -616 | 2,484,192 | -0.02 | 0.46 | -283 | 1,142,728 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -616 | 2,484,192 | -0.02 | 0.46 | -283 | 1,142,728 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 17,080 | 2,484,808 | 0.69 | 0.02 | 342 | 49,696 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 17,080 | 2,484,808 | 0.69 | 0.02 | 342 | 49,696 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 17,080 | 2,484,808 | 0.69 | 0.02 | 342 | 49,696 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -616 | 7,298,474 | -0.01 | 0.46 | -283 | 3,357,298 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -98,570 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,729 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,729 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,729 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -850 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -499 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,570 | -0.06 | 0.46 | -29 | 45,342 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,570 | -0.06 | 0.46 | -29 | 45,342 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,570 | -0.06 | 0.46 | -29 | 45,342 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,729 | 98,633 | 1.78 | 0.02 | 35 | 1,973 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,729 | 98,633 | 1.78 | 0.02 | 35 | 1,973 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,729 | 98,633 | 1.78 | 0.02 | 35 | 1,973 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -32 | 93,572 | -0.03 | 0.46 | -15 | 43,043 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 850 | 93,604 | 0.92 | 0.02 | 17 | 1,872 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -39 | 92,754 | -0.04 | 0.46 | -18 | 42,667 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 499 | 92,793 | 0.54 | 0.04 | 20 | 3,712 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -98,352 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,724 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,724 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,724 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -847 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -464 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,352 | -0.06 | 0.46 | -29 | 45,242 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,352 | -0.06 | 0.46 | -29 | 45,242 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,352 | -0.06 | 0.46 | -29 | 45,242 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,724 | 98,415 | 1.78 | 0.02 | 34 | 1,968 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,724 | 98,415 | 1.78 | 0.02 | 34 | 1,968 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,724 | 98,415 | 1.78 | 0.02 | 34 | 1,968 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -31 | 93,369 | -0.03 | 0.46 | -14 | 42,950 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 847 | 93,400 | 0.92 | 0.02 | 17 | 1,868 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -37 | 92,553 | -0.04 | 0.46 | -17 | 42,574 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 464 | 92,590 | 0.50 | 0.04 | 19 | 3,704 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | 11,190 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -703,655 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12,183 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12,183 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12,183 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -5,988 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12,021 | 0 | -100.00 | ||||
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -440 | 703,655 | -0.06 | 0.46 | -202 | 323,681 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -440 | 703,655 | -0.06 | 0.46 | -202 | 323,681 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -440 | 703,655 | -0.06 | 0.46 | -202 | 323,681 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12,183 | 704,095 | 1.76 | 0.02 | 244 | 14,082 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12,183 | 704,095 | 1.76 | 0.02 | 244 | 14,082 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12,183 | 704,095 | 1.76 | 0.02 | 244 | 14,082 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -216 | 668,426 | -0.03 | 0.46 | -99 | 307,476 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 5,988 | 668,642 | 0.90 | 0.02 | 120 | 13,373 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -927 | 662,654 | -0.14 | 0.46 | -426 | 304,821 | |
2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12,021 | 663,581 | 1.84 | 0.04 | 481 | 26,543 | |
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -631,133 | 0 | -100.00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -629,851 | 0 | -100.00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -819,493 | 0 | -100.00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,053,201 | 0 | -100.00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -774,527 | 0 | -100.00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -128,567 | 0 | -100.00 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 741,755 | 2,374,571 | 45.43 | ||||
2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 1,632,816 | 1,632,816 | |||||
2014-06-25 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common Stock |
J - Other | -1,930,369 | 1,930,369 | -50.00 | ||||
2014-06-05 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4,205 | 4,205 | |||||
2014-03-24 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Stock Option |
A - Award | 16,143 | 16,143 | |||||
2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | -525,500 | 0 | -100.00 | ||||
2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | -3,000,000 | 0 | -100.00 | ||||
2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 93,008 | 656,490 | 16.51 | ||||
2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 530,974 | 563,482 | 1,633.36 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -420,053 | 0 | -100.00 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,680,213 | 0 | -100.00 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1,050,000 | 0 | -100.00 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -4,200,000 | 0 | -100.00 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -9,000,000 | 0 | -100.00 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 32,912 | 293,268 | 12.64 | 10.00 | 329,120 | 2,932,680 | |
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 131,722 | 1,173,149 | 12.65 | 10.00 | 1,317,220 | 11,731,490 | |
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 214,095 | 1,907,008 | 12.65 | 10.00 | 2,140,950 | 19,070,080 | |
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 231,504 | 260,356 | 802.38 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 926,017 | 1,041,427 | 802.37 | ||||
2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 1,417,323 | 1,692,913 | 514.29 | ||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65,016 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65,016 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65,016 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65,016 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65,016 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
275,590 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
115,410 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
28,852 | ||||||||
2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
No securities are beneficially owned |
0 | ||||||||
2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -20,300 | 1,693,551 | -1.18 | 24.09 | -489,027 | 40,797,644 | |
2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -904 | 1,713,851 | -0.05 | 25.10 | -22,690 | 43,017,660 | |
2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -54,000 | 1,714,755 | -3.05 | 24.20 | -1,306,800 | 41,497,071 | |
2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -155,583 | 1,768,755 | -8.09 | 25.03 | -3,894,242 | 44,271,938 | |
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series D Preferred Stock |
C - Conversion | -407,060 | 0 | -100.00 | ||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series C-1 Preferred Stock |
C - Conversion | -333,288 | 0 | -100.00 | ||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series C Preferred Stock |
C - Conversion | -416,667 | 0 | -100.00 | ||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series B Preferred Stock |
C - Conversion | -1,900,000 | 0 | -100.00 | ||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series A Preferred Stock |
C - Conversion | -984,640 | 0 | -100.00 | ||||
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Common Stock |
P - Purchase | 20,000 | 1,562,616 | 1.30 | 15.00 | 300,000 | 23,439,240 | |
2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Common Stock |
C - Conversion | 1,542,616 | 1,542,616 | |||||
2013-09-18 | 3 | XLRN |
ACCELERON PHARMA INC
Common Stock |
4,867 | ||||||||
2013-07-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Series C-2 Convertible Preferred Stock |
C - Conversion | -617,031 | 0 | -100.00 | ||||
2013-07-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Series A Convertible Preferred Stock |
C - Conversion | -10,000,000 | 0 | -100.00 | ||||
2013-07-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 3,860,738 | 3,860,738 | |||||
2013-06-14 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4,205 | 4,205 | |||||
2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Series B Preferred Stock |
C - Conversion | -4,131,552 | 0 | -100.00 | ||||
2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Series A Preferred Stock |
C - Conversion | -8,640,289 | 0 | -100.00 | ||||
2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
P - Purchase | 107,142 | 1,924,339 | 5.90 | 14.00 | 1,499,988 | 26,940,746 | |
2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
C - Conversion | 550,873 | 1,817,197 | 43.50 | 7.73 | 4,258,248 | 14,046,933 | |
2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
C - Conversion | 1,152,039 | 1,266,324 | 1,008.04 | 5.25 | 6,048,205 | 6,648,201 | |
2013-05-08 | 3 | RCPT |
Receptos, Inc.
Common Stock |
114,285 | ||||||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series C Convertible Participating Preferred Stock |
C - Conversion | -19,544,924 | 0 | -100.00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series C Convertible Participating Preferred Stock |
C - Conversion | -9,626,604 | 0 | -100.00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series B Convertible Participating Preferred Stock |
C - Conversion | -11,422,045 | 0 | -100.00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series A-2 Convertible Participating Preferred Stock |
C - Conversion | -2,726,088 | 0 | -100.00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series A-1 Convertible Participating Preferred Stock |
C - Conversion | -2,090,000 | 0 | -100.00 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 491,824 | 1,165,786 | 72.98 | 7.00 | 3,442,768 | 8,160,502 | |
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 673,962 | 673,962 | |||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 331,953 | 891,887 | 59.28 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 393,863 | 559,934 | 237.17 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 94,003 | 166,071 | 130.44 | ||||
2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 72,068 | 72,068 | |||||
2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 1,050,000 | 1,764,286 | 147.00 | 2.00 | 2,100,000 | 3,528,572 | |
2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 500,000 | 2,851,447 | 21.26 | 2.00 | 1,000,000 | 5,702,894 | |
2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 75,000 | 215,013 | 53.57 | 2.00 | 150,000 | 430,026 | |
2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 125,000 | 651,560 | 23.74 | 2.00 | 250,000 | 1,303,120 | |
2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 250,000 | 2,434,800 | 11.44 | 2.00 | 500,000 | 4,869,600 | |
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -298,137 | 0 | -100.00 | ||||
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -6,422 | 0 | -100.00 | ||||
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -6,422 | 0 | -100.00 | ||||
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -6,422 | 0 | -100.00 | ||||
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -2,353 | 0 | -100.00 | ||||
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -23 | 298,137 | -0.01 | 5.83 | -134 | 1,738,139 | |
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -23 | 298,137 | -0.01 | 5.83 | -134 | 1,738,139 | |
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 6,422 | 298,160 | 2.20 | 0.02 | 128 | 5,963 | |
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 6,422 | 298,160 | 2.20 | 0.02 | 128 | 5,963 | |
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -23 | 285,339 | -0.01 | 5.83 | -134 | 1,663,526 | |
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 6,422 | 285,362 | 2.30 | 0.02 | 128 | 5,707 | |
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -13 | 278,940 | 0.00 | 5.83 | -76 | 1,626,220 | |
2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 2,353 | 278,953 | 0.85 | 0.03 | 71 | 8,369 | |
2012-06-13 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4,205 | 4,205 | |||||
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -130,867 | 0 | -100.00 | ||||
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -7,001 | 0 | -100.00 | ||||
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -7,001 | 0 | -100.00 | ||||
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -7,001 | 0 | -100.00 | ||||
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -2,580 | 0 | -100.00 | ||||
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -2,497 | 0 | -100.00 | ||||
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -36 | 130,867 | -0.03 | 3.95 | -142 | 516,925 | |
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -36 | 130,867 | -0.03 | 3.95 | -142 | 516,925 | |
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -36 | 130,867 | -0.03 | 3.95 | -142 | 516,925 | |
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 7,001 | 130,903 | 5.65 | 0.02 | 140 | 2,618 | |
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 7,001 | 130,903 | 5.65 | 0.02 | 140 | 2,618 | |
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 7,001 | 130,903 | 5.65 | 0.02 | 140 | 2,618 | |
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -14 | 109,972 | -0.01 | 3.95 | -55 | 434,389 | |
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 2,580 | 109,986 | 2.40 | 0.02 | 52 | 2,200 | |
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -19 | 107,406 | -0.02 | 3.95 | -75 | 424,254 | |
2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 2,497 | 107,425 | 2.38 | 0.03 | 75 | 3,223 | |
2012-02-29 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4,205 | 4,205 |